Clinical Trial Detail

NCT ID NCT03254927
Title A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celldex Therapeutics
Indications

oropharynx cancer

head and neck squamous cell carcinoma

Therapies

CDX-3379 + Cetuximab

Age Groups: senior adult

No variant requirements are available.